Xellia Pharmaceuticals

Explore Xellia's portfolio of anti-infective APIs — including Vancomycin, Daptomycin, Colistimethate Sodium, and more — for regulated markets worldwide

High-quality fermentation-based anti-infective APIs & injectable FDFs for regulated markets worldwide. Explore Xellia's full product portfolio

High-quality injectable anti-infective FDFs for demanding clinical settings. Safe, effective, and consistently supplied by Xellia Pharmaceuticals

Dalbavancin, Fidaxomicin, and more in development. Discover Xellia's growing pipeline of anti-infective APIs and finished dosage forms

Xellia and Hisun sign strategic global multiple-API partnership

Xellia Pharmaceuticals employs over 1,100 people across 10 sites, working to combat infections.

Alex Sproedt leads operations at Xellia as COO — driving procurement, supply chain, and manufacturing performance that keeps critical medicines moving

Meet Florian Falch, Chief Business Officer at Xellia Pharmaceuticals. Bringing strategy, transformation, and M&A expertise from Sandoz and KPMG

Gaël Bernard leads Xellia's global commercial organization as CCO, with decades of pharmaceutical leadership experience across Europe and Asia

The page introduces the leadership team at Xellia Pharmaceuticals, highlighting their role in guiding over 120 years of anti-infective innovation.

The page highlights Xellia Pharmaceuticals’ team and its over 120 years of focus on anti-infective medicines.

120+ years of anti-infective expertise. From fermentation-based manufacturing to regulatory excellence, Xellia delivers the capabilities you can build on

Xellia Pharmaceuticals, owned by Novo Holdings, traces its pharmaceutical expertise back over 120 years in anti-infectives.

The page provides contact details for Xellia Pharmaceuticals in Copenhagen and its global team for API, FDF, sales, and partnerships.

The page offers support contact for questions or assistance, connecting users with the appropriate team.

The page directs users to file product quality complaints.

Your trusted partner for anti-infective APIs and finished dosage forms. Fermentation-based manufacturing with 120+ years of proven supply.

The page explains how Xellia Pharmaceuticals collects, processes, and discloses personal data when receiving adverse event reports.

Xellia Pharmaceuticals prioritizes data protection and confidentiality, outlining its privacy policy for personal data processing.

Xellia Pharmaceuticals upholds integrity, compliance, and uniform standards across its global operations.

Xellia Group is owned by Novo Holdings A/S since July 2013 and the Group is headquartered in Copenhagen, Denmark. The Xellia Group is a leading specialty pharmaceutical company, focusing on anti-infective treatments against serious and often life-threatening infections.